AOD-9604 vs Tesamorelin

Written by the Pure Peptides editorial team

Reviewed by Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer · Reviewed

Published · Updated · 12 references

AOD-9604 and Tesamorelin are different molecules: AOD-9604 is a modified 16-residue peptide from the C-terminal end of human growth hormone; Tesamorelin is a 44-residue analog of human growth hormone-releasing hormone.

vs
Tesamorelin

Tesamorelin

View Tesamorelin

Structure at a glance

Each chain as stored in the product database, one box per residue. The two are drawn separately; no alignment between them is implied.

AOD-9604 · 16 residues

Tesamorelin · 44 residues

Hex: N-terminal trans-3-hexenoyl group. NH2: C-terminal amide. Letters are one-letter amino acid codes.

Chain length
AOD-960416 residues
Tesamorelin44 residues
Molecular weight
AOD-96041,815.10 g/mol
Tesamorelin5,135.86 g/mol

Drawn from the product database. Each measure's bars share one scale.

AOD-9604 vs Tesamorelin, compared
What it isA 16-residue peptide: residues 177 to 191 at the C-terminal end of human growth hormone, with a tyrosine in place of the phenylalanine at position 176.[1]A 44-residue peptide: an analog of human growth hormone-releasing hormone with an N-terminal trans-3-hexenoyl group.
How they relateDifferent molecules from different parents. AOD-9604 corresponds to residues 177 to 191 of human growth hormone, with an N-terminal tyrosine in place of phenylalanine 176.[1] Tesamorelin is an analog of the full 44-residue human growth hormone-releasing hormone.
CAS number221231-10-3218949-48-5
Molecular formulaC78H123N23O23S2C221H366N72O67S
Molecular weight1,815.10 g/mol5,135.86 g/mol
SequenceYLRIVQCRSVEGSCGFtrans-3-hexenoyl-YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH2
Evidence baseHuman trials: six randomized trials in about 900 adults; the one peer-reviewed report, developer-funded, covers safety only.[2] The pivotal trial missed its primary endpoint.[3] Three later placebo-controlled trials, in other indications, found no significant effect.[12]Human studies, which supported an approval for one indication. A pooled analysis of two phase 3 trials covered 806 randomized participants.[4] Their primary endpoints were imaging surrogates. The trial papers were manufacturer-sponsored.
Regulatory statusNo United States or European drug approval.[5] FDA states that neither its free base nor its acetate is a component of an approved drug.[5]The FDA approved tesamorelin acetate in 2010 for one therapeutic indication.[6][7] That approval is current.
Compared head-to-head?No direct comparison found in PubMed (searched October 2026).[8]
Handling differenceAOD-9604 contains one disulfide bridge, which reducing agents open. Tesamorelin contains no cysteine, so it has no disulfide; its single methionine oxidizes on air exposure.

How AOD-9604 and Tesamorelin differ

AOD-9604 and Tesamorelin are different molecules from different parents. AOD-9604 is a synthetic 16-residue peptide from the C-terminal end of human growth hormone. It corresponds to residues 177 to 191 of that hormone, with a tyrosine in place of the phenylalanine at position 176.[1] Its two cysteines are joined in a disulfide bridge, so part of the chain is a closed loop. Tesamorelin is a synthetic analog of the full 44-residue human growth hormone-releasing hormone, with a trans-3-hexenoyl group on its N-terminus. It contains no cysteine, so no disulfide is possible.

In people, AOD-9604 was tested in six randomized trials in about 900 adults.[2] The one peer-reviewed report of their pooled data covers safety only.[2] The compound's developer funded both safety papers, that report among them, and its chief executive, who held a stake in the parent company, co-authored them.[2] In a 2024 briefing document, FDA reported that AOD-9604's phase 2b trial missed its primary endpoint, and that the developer terminated development for that trial's indication in 2007.[3] Three later randomized placebo-controlled trials of the same peptide, in other indications, found no significant difference from placebo on their primary measures.[12] In a separate AOD-9604 trial in 300 adults, four cancers and one benign lipoma occurred, all in active arms and none on placebo.[2]

A pooled analysis of Tesamorelin's two phase 3 trials covered 806 randomized participants.[4] In the literature reviewed for Tesamorelin, those trials used imaging surrogates as primary endpoints, not clinical outcomes. The two trial papers and the pooled analysis were manufacturer-sponsored, with sponsor-affiliated co-authors. A randomized phase 2 trial of 73 participants, in another indication, found no significant difference on the measure reported for it.[9] In the first of the two randomized placebo-controlled phase 3 trials, withdrawal because of an adverse event was higher on Tesamorelin than on placebo.[10]

AOD-9604 holds no United States or European drug approval.[5] FDA states that neither its free base nor its acetate is a component of an approved drug.[5] The FDA approved tesamorelin acetate in 2010 for one therapeutic indication.[6][7] That approval is current, and it belongs to tesamorelin acetate and that one indication. Tesamorelin acetate is the active ingredient of a prescription medicine sold under another name. The material supplied here is a research-grade preparation, is not that medicine, and holds no marketing authorization. That medicine's label lists glucose intolerance or new diabetes among its warnings; HbA1c reached 6.5% or above in 5% of participants on the drug against 1% on placebo.[11]

AOD-9604 contains one disulfide bridge. Reducing agents open it, and at alkaline pH disulfides can exchange between molecules, which may give dimers and larger aggregates. Tesamorelin's single sulfur is in a methionine, which oxidizes to a sulfoxide on air exposure, adding sixteen mass units. Tesamorelin may also aggregate on repeated freezing and thawing.

Have AOD-9604 and Tesamorelin been compared directly?

No direct comparison of AOD-9604 with Tesamorelin was found in a PubMed search run in October 2026.[8] That search covers PubMed only.

Read more on each compound

Frequently Asked Questions

Is AOD-9604 the same as Tesamorelin?+

AOD-9604 and Tesamorelin are different molecules from different parents. AOD-9604 is a 16-residue peptide from the C-terminal end of human growth hormone, with a tyrosine in place of the phenylalanine at position 176. Tesamorelin is an analog of the full 44-residue human growth hormone-releasing hormone, with a trans-3-hexenoyl group on its N-terminus.

Is AOD-9604 or Tesamorelin approved?+

AOD-9604 holds no United States or European drug approval; the FDA approved tesamorelin acetate in 2010 for one therapeutic indication. Tesamorelin acetate is the active ingredient of a prescription medicine sold under another name. The material supplied here is a research-grade preparation, is not that medicine, and holds no marketing authorization.

References

  1. 1
    Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D. Drug Testing and Analysis. 2015. PMID 25208511. DOI: 10.1002/dta.1715.
  2. 2
    Pooled safety report, 2013. DOI: 10.4021/jem157w. Not indexed in PubMed; no PMID, so the DOI was resolved on Crossref on 28 August 2026 and the title and author line confirmed there. The only peer-reviewed publication reporting primary pooled data from the AOD-9604 human program; it reports safety only. doi.org
  3. 3
    US Food and Drug Administration. Briefing Document, Pharmacy Compounding Advisory Committee meeting, 4 December 2024 (memo dated 5 November 2024), including its Nonclinical Assessment section. Underlying disclosure by the compound's developer, 21 February 2007, SEC-filed. No PMID or DOI. fda.gov
  4. 4
    Pooled analysis of two phase 3 trials, 2010. PMID 20554713.
  5. 5
    openFDA drug/label and drug/drugsfda endpoints, field-qualified on openfda.substance_name, openfda.generic_name and openfda.brand_name, queried 27 August 2026, with control queries confirming the fields are populated; EMA European Public Assessment Report dataset, same date; FDA Briefing Document 4 December 2024, p. 7; the developer's ASX announcement, 26 April 2013.
  6. 6
    US Food and Drug Administration, Center for Drug Evaluation and Research. Approval letter for tesamorelin, 10 November 2010 (Reference ID 2863003).
  7. 7
    US Food and Drug Administration, Drugs@FDA. Approval record whose active ingredient is tesamorelin acetate; marketing status Prescription. Retrieved via api.fda.gov/drug/drugsfda.json on products.active_ingredients.name "TESAMORELIN ACETATE", 3 October 2026.
  8. 8

    PubMed search, 3 October 2026 (records to 2 October 2026)

    3 records; none was a direct comparison of the two compounds.

    Exact query (NCBI E-utilities): ("AOD-9604"[tiab] OR "AOD9604"[tiab] OR "AOD 9604"[tiab] OR "Tyr-hGH"[tiab]) AND ("tesamorelin"[tiab] OR "hexenoyl"[tiab] OR "trans-3-hexenoyl"[tiab]) AND ("1800/01/01"[edat] : "2026/10/02"[edat])

    View this search on PubMed
  9. 9
    Ellis RJ, Vaida F, Hu K, Dube M, Henry B, Chow F, et al. 2025;231(5):1230-1238. PMID 39813152.
  10. 10
    Phase 3 trial report, 2007. PMID 18057338.
  11. 11
    US Food and Drug Administration. Approved prescribing information for tesamorelin acetate; label version 29 July 2026. Retrieved via openFDA drug/label.
  12. 12
    ClinicalTrials.gov records NCT03865953, NCT04153409 and NCT05298306, read 16 October 2026: three completed randomized, double-blind, placebo-controlled crossover trials of the same peptide under a later development code, each with results posted and none significant on its primary measure. The EU Clinical Trials Register, EudraCT 2018-004534-15, records that code as previously AOD9604.
Dr. Martina Rossi, PhD

Reviewed for scientific accuracy

Dr. Martina Rossi, PhD

PhD, Université Grenoble Alpes · Scientific Contributor and Reviewer

Dr. Rossi's doctoral research at Université Grenoble Alpes examined the vascular functions of bone morphogenetic proteins. Her peer-reviewed work spans cell and molecular biology, vascular biology, and gene therapy, in journals including Cardiovascular Research, Scientific Reports, and Brain Sciences. She reviews Pure Peptides' product, reference, and research pages for scientific accuracy against the sources they cite.

Reviewed ORCIDGoogle ScholarTeam profile →
Comparison

AOD-9604 vs HGH Fragment 176-191

AOD-9604 and HGH Fragment 176-191 are 16-residue peptides from the C-terminal end of human growth hormone that differ at one position.

Read Comparison
Comparison

CJC-1295 (No DAC) vs Tesamorelin

CJC-1295 (No DAC) carries four substitutions in human GHRH's first 29 residues; Tesamorelin is an analog of the full 44-residue hormone.

Read Comparison
Comparison

HGH Fragment 176-191 vs Tesamorelin

HGH Fragment 176-191 is a 16-residue fragment of human growth hormone; Tesamorelin is a 44-residue analog of human GHRH.

Read Comparison